US 2014/0193802 A1 · IDENTIFICATION OF AN ALTERED THERAPEUTIC SUSCEPTIBILITY TO ANTI-HCMV COMPOUNDS AND OF A RESISTANCE AGAINST ANTI-HCMV COMPOUNDS

Abstract

The present invention relates to a method for the detection of an altered therapeutic response of a subject infected by HCMV to a treatment with a 3,4 dihydroquinazoline or N-{3-[({4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide, a method for the detection of a drug resistance of a HCMV to a 3,4-dihydroquinazoline or N-{3-[({4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide, and to a method for the detection of a mutation of a HCMV resulting in a drug resistance to a 3,4-dihydroquinazoline or N-{3-[({4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide.

Claims42

Dependent claims

A method for the identification of an altered therapeutic susceptibility of a subject infected by HCMV to a treatment with a 3,4 dihydroquinazoline or a compound of Formula (X)

i.e., N-{3-[({4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide,
comprising the following steps:
(1) providing genetic material of the HCMV isolated from said subject,
(2) screening said genetic material for at least one mutation in the ORF UL56, and
(3) correlating a positive finding in step (2) with the presence of a reduced therapeutic susceptibility.

2 more elements

An in vitro method for use in the identification of an altered therapeutic susceptibility of a subject infected by HCMV to a 3,4 dihydroquinazoline or the compound of Formula (X)

i.e. N-{3-[({4-[5-(6-Aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide,
comprising the following steps:
(1) providing genetic material of the HCMV from a subject infected with HCMV,
(2) screening said genetic material for at least one mutation in the ORF UL56, and
(3) correlating a positive finding in step (2) with a reduced therapeutic susceptibility.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

13/940,149Filed 11 Jul 2013

Priority

11 Jul 2012

Published

10 Jul 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

C12Q 1/705
Specific hybridization probes: for herpetoviridae, e.g. herpes simplex, varicella zoster
A61K 31/4439
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/517
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
C12Q 2600/106
Oligonucleotides characterized by their use: pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Identification of an altered therapeutic susceptibility to anti-hcmv compounds and of a resistance against anti-hcmv compounds

Life of this patent

Identification of an altered therapeutic susceptibility to anti-hcmv compounds and of a resistance against anti-hcmv compounds

Life of this patent

Abstract

Claims42